Open Access: View PDF

DOI: 10.21088/jpn.2277.9035.14225.4

Abstract

Ketamine, traditionally known as an anesthetic agent, has garnered attention for its rapid acting antidepressant properties, particularly in patients with treatment resistant depression (TRD). The compound’s unique pharmacological profile primarily as an NMDA receptor antagonist has enabled its repositioning in psychiatric settings, where conventional antidepressants often fall short. This review delves into the evolving role of ketamine in psychiatry, examining its mechanisms of action, therapeutic applications, clinical efficacy, safety concerns, and emerging trends in the field. While ketamine therapy offers promise, its use raises ethical, regulatory, and long-term safety considerations that require continued research and careful implementation.
 

Keywords : • Ketamine • Psychiatry • Depression • NMDA receptor • Antidepressant • Treatment-resistant depression • Mental health • Suicidality • Glutamatergic system • Neuroplasticity

Corresponding Author : Asif Khan.